Ece Cakiroglu

Ece Cakiroglu

Auto-generated profile, based on publicly available information

Ece Cakiroglu

Izmir Biomedicine and Genome Center, Izmir, Turkey

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
ECEce Cakiroglu
Ece Cakiroglu
SESude Eris
Sude Eris
OOOzden Oz
Ozden Oz
GKGökhan Karakülah
Gökhan Karakülah
SSSerif Senturk
Serif Senturk
Malignant pleural mesothelioma (MPM) is a rare yet highly aggressive malignancy with a severe prognosis. Compounded by the lack of effective treatment modalities, MPM remains a formidable health challenge. Therefore, the identification of actionable liabilities is critical for advancing precision medicine to combat this lethal disease. Here, we exploit an unbiased genome-wide CRISPR screen, integrating and cross-comparing three MPM cell lines with nonmalignant mesothelial cells, to selectively map the gene targets whose depletion indicates a common dependency in MPM cells. This systematic approach unveils a cohort of verifiable genes, among which BUB1, a mitotic checkpoint serine/threonine kinase, emerges as a high-confidence hit in cancer cells. Cellular and molecular studies demonstrate that genetic depletion or pharmacological inhibition of BUB1 profoundly impairs MPM cell survival and growth while inducing G2/M cell cycle arrest, cellular senescence, and apoptosis, and attenuating functional hallmarks of aggressive cancer cells. Transcriptomic profiling of BUB1-depleted cells discloses differential gene expression signatures congruent with cell fate phenotypes, including the reprogramming of mitotic network genes. Mechanistically, BUB1 is indispensable for the proper localization of essential mitotic regulators MAD1, MAD2, and Shugoshin (SGO1), thereby ensuring the functionality of the spindle assembly checkpoint (SAC). Furthermore, BUB1 ablation leads to cytokinesis failure and multinucleation, a phenotype characterized by the downregulation of CDC20, Cyclin A, and Cyclin B, and a reciprocal upregulation of the cyclin-dependent kinase inhibitor p21. Clinically, MPM tumors exhibit elevated levels of BUB1, and high BUB1 expression is associated with shorter patient survival. Our novel findings accentuate comparative CRISPR screens as a powerful platform to explore tumor cell-selective gene essentiality and propose BUB1 kinase as a potential marker and druggable vulnerability with therapeutic implications for MPM.

10 January 2023 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
IUIlkay tugba Unek
Ilkay tugba Unek
IOIlhan Oztop
Ilhan Oztop
YBYasemin Basbinar
Yasemin Basbinar
TUTARKAN UNEK
TARKAN UNEK
ALAsim Leblebici
Asim Leblebici
İAİbrahim Astarcıoğlu
İbrahim Astarcıoğlu
Background: Circulating tumor cells (CTCs) are cancer cells which separate from the primary tumor and enter systemic circulation. In this study, it was aimed to examine the relationship between CTCs isolated and identified from the peripheral blood of patients with pancreatobiliary cancer, with the clinicopathological characteristics of the patients and their overall survival. Methods: A total of 21 patients were included the study. Density gradient centrifugation with the OncoQuick® assay was performed for isolation of CTCs from peripheral blood. In order to identify CTCs, enriched samples underwent flow cytometric analysis. Results: The rate of patients with positive surgical margin in the high CTC group (CTC >15) was identified to be statistically significantly high compared to the group with low CTC (CTC ≤15) (83.3% vs. 16.7%; P = .041). Median neutrophil/lymphocyte ratio (NLR) was found to be higher in the high CTC group compared to the low CTC group, which was close to statistical significance (2.37 vs. 1.41; P = .055). Conclusions: Circulating tumor cells were identified to have a significant relationship with surgical margin positivity in our study for the first time, suggesting that the CTCs count in peripheral blood in preoperative patients may be a biomarker predicting positive surgical margin. Due to the very low number of studies assessing the relationship between CTCs and NLR, our study which identified relationship close to statistical significance between CTCs and NLR, significantly contributes to the literature on the topic of the possible role of lymphocytes in CTC clearance. Cite this article as: Ünek İT, Öztop İ, Başbınar Y, et al. The prognostic significance of circulating tumor cells in patients with pancreatobiliary cancer. Turk J Gastroenterol. 2023;34(3):278-286.

14 March 2025 in Molecular Oncology
Verified
Journal Article
Open access
MKMinenur Kalyoncu
Minenur Kalyoncu
Dilara DemirciDilara Demirci
Dilara Demirci
SESude Eris
Sude Eris
BDBengisu Dayanc
Bengisu Dayanc
ECEce Cakiroglu
Ece Cakiroglu
SSSerif Senturk
Serif Senturk
Transforming growth factor‐β (TGF‐β) signaling and cellular senescence are key hallmarks of hepatocellular carcinoma (HCC) pathogenesis. Despite provoking senescence‐associated growth arrest in epithelial HCC cells, elevated TGF‐β activity paradoxically correlates with increased aggressiveness and poor prognosis in advanced tumors. Whether the transition between these dichotomous functions involves modulation of the senescence phenotype during disease progression remains elusive. Exploiting the epithelial HCC cell line Huh7 as a robust model, we demonstrate that chronic exposure to TGF‐β prompts escape from Smad3‐mediated senescence, leading to the development of TGF‐β resistance. This altered state is characterized by an optimal proliferation rate and the acquisition of molecular and functional traits of less‐differentiated mesenchymal cells, coinciding with differential growth capacity in 2D and 3D culture conditions, epithelial‐to‐mesenchymal transition (EMT), and increased invasiveness in vitro, and metastasis in vivo. Mechanistically, resistant cells exhibit defective activation and nuclear trafficking of Smad molecules, particularly Smad3, as ectopic activation of the TGF‐β/Smad3 axis is able to reinstate TGF‐β sensitivity. An integrated transcriptomic landscape reveals both shared and distinct gene signatures associated with senescent and TGF‐β resistant states. Importantly, genetic ablation and molecular studies identify microtubule affinity regulating kinase 1 (MARK1) and glutamate metabotropic receptor 8 (GRM8) as critical modulators of the resistance phenomenon, potentially by impairing spatiotemporal signaling dynamics of Smad activity. Our findings unveil a novel phenomenon wherein epithelial HCC cells may exploit senescence plasticity as a mechanism to oppose TGF‐β anti‐tumor responses and progress towards more aggressive HCC phenotypes.

1 May 2023 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
IUIlkay tugba Unek
Ilkay tugba Unek
IOIlhan Oztop
Ilhan Oztop
YBYasemin Basbinar
Yasemin Basbinar
TUTARKAN UNEK
TARKAN UNEK
ALAsim Leblebici
Asim Leblebici
İAİbrahim Astarcıoğlu
İbrahim Astarcıoğlu
Background: Hepatocyte growth factor is a cytokine secreted by the stromal cells in the tumor microenvironment. There is little information about the clinical significance of serum hepatocyte growth factor level in patients diagnosed with pancreatobiliary cancer. The objective of the current study was to investigate the relationship between serum hepatocyte growth factor level with inflammation markers and the clinical features of patients with pancreatobiliary cancer. Methods: A total of 62 patients with pancreatobiliary cancer were included in this study. Serum hepatocyte growth factor concentrations were evaluated utilizing the enzyme-linked immunosorbent assay method. Results: The median serum hepatocyte growth factor level was 329.1 ng/mL (1.4-1051.1). The patients were categorized into 2 groups as those below the median hepatocyte growth factor level (low hepatocyte growth factor) and those above the median hepatocyte growth factor level (high hepatocyte growth factor). While 40.9% of the patients without metastasis were observed to be in the high hepatocyte growth factor group, 72.2% of the metastatic patients were observed to be in the high hepatocyte growth factor group (P = .025). The median levels of monocyte, monocyte-to-lymphocyte ratio, C-reactive protein, and C-reactive protein-to-albumin ratio were found to be significantly higher in the high hepatocyte growth factor group as compared to the low hepatocyte growth factor group (P < .050). Conclusion: The significant relationship between serum hepatocyte growth factor level and systemic inflammation markers in patients with pancreatobiliary cancer is shown for the first time in our study. This study, which showed a significant relationship between the presence of metastasis and serum hepatocyte growth factor level, suggests that serum hepatocyte growth factor level may be a prognostic biomarker in patients who are diagnosed with pancreatobiliary cancer. Cite this article as: Ünek İT, Öztop İ, Başbınar Y, et al. Association of serum hepatocyte growth factor level with systemic inflammatory biomarkers in patients with pancreatobiliary cancer. Turk J Gastroenterol. 2023;34(5):568-575.